Evidence map›Paper›PMID 42667672›Full record

ArticleJournal of extracellular vesicles2026

Pharmacological Inhibition of Small Extracellular Vesicle Secretion by ALK5i SD-208 via Lysosomal Rerouting of CD63+ Compartments.

Rahul Sanwlani, Georgina H Thompson, Kyle Bramich, Ching-Seng Ang, Millie L Trowbridge, Chris E Duringer, Vlad Stolojan, Sean M Davidson, Konstantinos Savvatis, John H McVey and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of extracellular vesicles, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rahul SanwlaniSchool of Biosciences, University of Surrey, Guildford, UK.ORCID 0000-0002-0282-6768
Georgina H ThompsonSchool of Biosciences, University of Surrey, Guildford, UK.
Kyle BramichDepartment of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia.
Ching-Seng AngThe Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, Australia.
Millie L TrowbridgeSchool of Biosciences, University of Surrey, Guildford, UK.
Chris E DuringerSchool of Biosciences, University of Surrey, Guildford, UK.
Vlad StolojanAdvanced Technology Institute, University of Surrey, Guildford, UK.
Sean M DavidsonThe Hatter Cardiovascular Institute, University College London, London, UK.ORCID 0000-0001-5182-4980
Konstantinos SavvatisInherited Cardiovascular Diseases Unit, Barts Heart Centre, London, UK.
John H McVeySchool of Biosciences, University of Surrey, Guildford, UK.
Suresh MathivananDepartment of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia.ORCID 0000-0002-7290-5795
Aled ClaytonDivision of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Patrizia CamellitiSchool of Biosciences, University of Surrey, Guildford, UK.ORCID 0000-0002-1346-8089

Funding

British Heart Foundation PG/22/11172John Jacob Astor Charitable TrustRoyal Society RSG/R1/180198
6 · The paper itself

Abstract

Pharmacological tools to selectively modulate extracellular vesicle (EV) secretion are scarce. Here, we identify the ALK5 (TGF-β receptor I) inhibitor SD-208 as a potent suppressor of small EV (sEV) secretion that acts independently of its canonical anti-fibrotic activity. SD-208 not only reversed myofibroblast activation but also markedly inhibited sEV secretion. Strikingly, this inhibitory effect persisted in non-activated cardiac fibroblasts and non-fibrotic HEK293 cells, demonstrating that SD-208 regulates EV secretion through mechanisms uncoupled from TGF-β/Smad signalling. Mechanistic analyses revealed that SD-208 disrupts vesicle trafficking rather than EV biogenesis. Reduced secretion of CD63

Indexed as

Extracellular VesiclesLysosomesReceptor, Transforming Growth Factor-beta Type ITetraspanin 30AnimalsFibroblastsHEK293 CellsHumansRatsSignal TransductionCD63 protein, humanReceptor, Transforming Growth Factor-beta Type ITetraspanin 30TGFBR1 protein, humanTgfbr1 protein, ratALK5 inhibitor (SD‐208)cardiac fibroblastsextracellular vesiclesfibrosishypertrophic cardiomyopathylysosome–autophagy pathwaymyofibroblastsTGF‐β signallingvesicle trafficking

Identifiers

PMID42667672
PMCPMC13525873

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.